Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Nia Impact Advisors LLC

Nia Impact Advisors LLC lessened its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 8.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,932 shares of the pharmaceutical company's stock after selling 1,395 shares during the period. Vertex Pharmaceuticals comprises about 2.1% of Nia Impact Advisors LLC's holdings, making the stock its 16th largest holding. Nia Impact Advisors LLC's holdings in Vertex Pharmaceuticals were worth $6,416,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Wedmont Private Capital raised its position in Vertex Pharmaceuticals by 11.8% during the 4th quarter. Wedmont Private Capital now owns 3,633 shares of the pharmaceutical company's stock valued at $1,488,000 after purchasing an additional 384 shares during the last quarter. Pallas Capital Advisors LLC raised its position in Vertex Pharmaceuticals by 3.1% during the 4th quarter. Pallas Capital Advisors LLC now owns 2,461 shares of the pharmaceutical company's stock valued at $991,000 after purchasing an additional 75 shares during the last quarter. Marcum Wealth LLC raised its position in Vertex Pharmaceuticals by 10.1% during the 4th quarter. Marcum Wealth LLC now owns 1,326 shares of the pharmaceutical company's stock valued at $534,000 after purchasing an additional 122 shares during the last quarter. Accurate Wealth Management LLC raised its position in Vertex Pharmaceuticals by 6.5% during the 4th quarter. Accurate Wealth Management LLC now owns 917 shares of the pharmaceutical company's stock valued at $375,000 after purchasing an additional 56 shares during the last quarter. Finally, Fifth Third Wealth Advisors LLC raised its position in Vertex Pharmaceuticals by 23.1% during the 4th quarter. Fifth Third Wealth Advisors LLC now owns 1,227 shares of the pharmaceutical company's stock valued at $494,000 after purchasing an additional 230 shares during the last quarter. Institutional investors own 90.96% of the company's stock.

Vertex Pharmaceuticals Stock Up 1.0%

NASDAQ VRTX traded up $4.27 during trading on Friday, reaching $438.65. 1,505,089 shares of the company's stock were exchanged, compared to its average volume of 1,409,926. The stock has a market cap of $112.64 billion, a P/E ratio of -199.39, a price-to-earnings-growth ratio of 2.11 and a beta of 0.51. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. The company has a 50 day moving average price of $482.97 and a two-hundred day moving average price of $464.51. Vertex Pharmaceuticals Incorporated has a 1 year low of $377.85 and a 1 year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing the consensus estimate of $4.29 by ($0.23). The company had revenue of $2.77 billion for the quarter, compared to analysts' expectations of $2.85 billion. Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. The firm's revenue was up 2.6% on a year-over-year basis. During the same period in the prior year, the company earned $4.76 earnings per share. On average, equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, EVP David Altshuler sold 3,231 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the transaction, the executive vice president now owns 26,512 shares in the company, valued at approximately $13,256,000. The trade was a 10.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Ourania Tatsis sold 244 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $455.06, for a total value of $111,034.64. Following the transaction, the executive vice president now owns 67,695 shares in the company, valued at $30,805,286.70. The trade was a 0.36% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 4,005 shares of company stock worth $1,978,465. Company insiders own 0.20% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. StockNews.com raised Vertex Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Tuesday, March 11th. Truist Financial upped their price target on Vertex Pharmaceuticals from $460.00 to $520.00 and gave the company a "buy" rating in a research report on Tuesday, February 11th. Morgan Stanley upped their target price on Vertex Pharmaceuticals from $462.00 to $464.00 and gave the stock an "equal weight" rating in a report on Tuesday, May 6th. The Goldman Sachs Group reiterated a "buy" rating on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. Finally, Bank of America upped their target price on Vertex Pharmaceuticals from $555.00 to $567.00 and gave the stock a "buy" rating in a report on Monday, March 31st. Thirteen investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Vertex Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $515.04.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.